FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

 

MEDIFIRST SOLUTIONS ANNOUNCES A CLINICAL STUDY FOR A BREAST CANCER DIAGNOSTIC MEDICAL DEVICE

 

Freehold, NJ – February 22, 2021 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), is pleased to announce it is a Sponsor and Collaborator for an upcoming breast cancer clinical study for real-time margin detection.

 

About 1 in 8 U.S. women will develop invasive breast cancer over the course of her lifetime. Besides skin cancer, breast cancer is the most commonly diagnosed cancer among American women. The purpose of this study is to evaluate the effectiveness and accuracy of the investigational diagnostics FLIM imaging device to provide direct support during lumpectomy cancer surgery to achieve the common goal of improving patient quality of life by decreasing the rates of re-operation.  It is estimated that up to 24% of women have a second surgery because the margins were not clear as per the pathology results. This causes great distress to the patient and adds additional burden to the hospital system and surgeons. We believe there is a need for real-time imaging, a device that can show us where tumor ends, and healthy tissue begins while the patient is still asleep on the operating table. 

 

The FLIM Diagnostics imaging device was created to improve patient quality of life by decreasing rates of re-operation. FLIM has the potential to be able to visualize cancer margins in real-time, during surgery and FLIM Diagnostic can potentially differentiate between cancerous and non-cancerous specimens. FLIM analysis by the surgeon will not take more than several minutes, therefore not adding any significant time for patient to be under anesthesia. All specimens will be (In-Vitro) removed from the patient’s body prior to their evaluation by the FLIM technique. FLIM margin results will be compared directly with pathology results for accuracy of the findings.

 

Breast-conserving surgery is a critical first step of treatment for many women with breast cancer. The goal is to remove all the cancer cells, leaving behind only healthy tissue. However, today, surgeons do not have a diagnostic device to determine if all cancer has been removed during the initial surgery; instead, patients must wait until days after surgery to find out if all the cancer has been removed and the margins were cleared. 

  

This study is to evaluate the FLIM Diagnostic ((Fluorescent Lifetime Imaging Microscopy), a medical device that can immediately, during surgery, analyze the removed breast tissue to confirm that the margins are cancer free. The removed tissue is not damaged and can still get sent out for routine pathology testing to confirm the results of the FLIM diagnostics technology. We further believe that this technology would present a dramatic improvement in treating breast cancer patients.

 

Every cell in the body contains mitochondria, so the FLIM has a high probability of serving as a platform technology. Failure to achieve clean margins in other cancer (liver, lung, pancreas, etc.) can have very serious consequences. Since mitochondria are not specific to any specific organs, the same FLIM technology can have the potential to technically be able to confirm margins for these other solid tumors as well.


Our goal is to provide the best outcomes for patients who must have surgery to remove cancer. One of the most important ways we do that is through innovative technology. The FLIM Diagnostics system has the potential to show promising results to improve confidence during lumpectomy procedures; for the numerous patients that will be enrolled in the Non-Significant risk clinical trial and prove our theory that the FLIM Diagnostics technology can show margin accuracy between 90 to 99 percent accuracy and the results will be compared directly with pathology results for proof of concept. There is no risk to the patient at any stage of this research protocol.

 

Medifirst anticipates an announcement with further specifics and details about the study and a general company update addressing its overall status and direction in the upcoming days and weeks. We appreciate all the support and patience by our shareholder through the pandemic and the last year. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.  

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

 

MEDIFIRST SOLUTIONS PROVIDES AN UPDATE TO THE GREATER NEW YORK DENTAL MEETING

 

Freehold, NJ – December 18, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared TTML-810/2000 Laser Thermal Therapeutic Device and Distributor of USA Premium Hemp and CBD products available at www.usapremiumcbd.com is pleased to provide a company update.

Medifirst recently exhibited its FDA Cleared Infrared Laser at the Greater New York  Dental Meeting at the Jacob K. Javits Convention Center in New York City. The Company presented its laser for the treatment of Oral Mucositis and TMJ. Clinical studies have shown the Infrared Laser to be very effective for patients who suffer from the pain and side effects of TMJ.

The launch of the OraMax RX Laser at the Dental Meeting, we believe was very successful in educating dentists, oral surgeons and dental professionals about our laser for the treatment of Oral Mucositis and TMJ pain.

 

We are currently following up with all the medical professionals we met at the show.  We found great interest from representatives of other countries for the laser. We are in the talks for international distribution and sales in Brazil, Mexico and Costa Rica and Japan. Regarding local markets, we are working to set up demos for the doctors in their office who have an interest to start using the laser technology in their practice.

 

Stated President Bruce J. Schoengood, “We are very thrilled the show was a success and we have had great feedback from other companies and professionals that attended and have showed great interest in our laser and to introduce the technology to their network of dentists and oral surgeons. Since the show runs into the holidays, and many people are not available until after the New Year, we anticipate further announcements in the upcoming weeks regarding our results of the show.”

  

About the Time Machine Laser
The Time Machine Laser is the only all-in-one, affordable, FDA cleared, Infrared, 810nm, 2000mW power, small, hand-held portable laser marketed for pain relief in the U.S.  The Time Machine Laser, which has been extensively tested and approved by Intertek for safety and electrical standards, has the power and frequency often found in large and expensive stationary units and at a fraction of the cost.  Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Lasers is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.  

------------------------------------------------

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES A COMPANY UPDATE FOR ITS LASER DIVISION

 

Freehold, NJ – October 8, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared TTML-810/2000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Premium Hemp and CBD products available at www.usacbdshopper.com is pleased to provide a company update.
 

As stated in recent announcements, one of the new areas the Company has been focusing on with its FDA cleared Infrared Laser, is to treat the side effects of cancer therapy called Oral Mucositis.  After working with an affiliate company to host three recent educational laser events, and getting very positive feedback, Medifirst plans to attend and exhibit at the Greater NY Dental Meeting November 29th to December 4th at the Jacob K. Javits Convention Center in New York City. The Company considers this a very high profile venue to present its laser for the treatment of Oral Mucositis and TMJ. Clinical studies have shown the Infrared Laser to be very effective for patients who suffer from the pain and side effects of TMJ. The Dental Meeting is considered the largest dental meeting in the United States with over 52,000 attendees. Additionally, working with an affiliate company, we anticipate several NYC dental practices to begin to offer the laser treatments for Oral Mucositis in the upcoming months.
 

In a major new development, two major healthcare providers have recently approved laser therapy billing for the treatment of Oral Mucositis. The term Photobiomodulation (the science behind the laser), we believe, is starting to become recognized as mainstream in medicine as health insurance providers and medical organizations are updating their policies and stating that (Low Light Laser Therapy, LLLT) laser treatments are accepted for Oral Mucositis. Commented Medifirst President Bruce J. Schoengood, “Having an approved CPT code is the gold standard for medical billing.  This is very exciting and positions Medifirst to present our Infrared laser to medical professionals that is billable with the proven laser technology. A business strategy we are implementing is to work with dentists, oral surgeons, ENTs, and Physical Therapists thereby expanding their medical services by offering a turn-key business model which can include our Aesthetic Laser Program called the Time Machine Program and our Head & Neck Laser Program for pain, inflammation, TMJ and Oral Mucositis.”

 

The Medifirst Infrared 810nm Laser can be used for patients who develop painful or debilitating ulcers in the soft tissues within the oral cavity.  According to industry statistics, Oral Mucositis affects roughly 400,000 patients annually in the United States, affecting their cheeks, lips, gums, inner cavity and tonsilary region which includes all of the soft tissues. Treatment options today are rather limited. Patients are usually given pain medication and/or antiseptic mouthwash. Beyond that, we believe, there's not much doctors can do for the painful condition that, at advanced stages, can inhibit a patient's ability to eat and speak.

  

About the Time Machine Laser
The Time Machine Laser is the only all-in-one, affordable, FDA cleared, Infrared, 810nm, 2000mW power, small, hand-held portable laser marketed for pain relief in the U.S.  The Time Machine Laser, which has been extensively tested and approved by Intertek for safety and electrical standards, has the power and frequency often found in large and expensive stationary units and at a fraction of the cost.  Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Lasers is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.  

 

 

 

________________________________________________

 

 

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

Medifirst Solutions Provides Company Update for Its Oral Mucositis Treatment Studies

 

Freehold, NJ – August 22, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-810/2000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Premium Hemp and CBD products available at www.usacbdshopper.com is pleased to provide a company update.

 

Medifirst is pleased to announce that they are working with its affiliate and consulting groups in setting up a clinical trial for the treatment in reducing Oral Mucositis that will include three testing locations. Medifirst recently announced a new expansion and direction for its Time Machine Therapeutic Laser for the application of Photobiomodulation (PBM) to treat a side effect of cancer therapy called Oral Mucositis. This would involve adding a new claim and a new name for the laser treatment program via an FDA pre-submission application for the FDA 510(k) cleared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. Discussions are underway with two Universities that have expressed interest to participate. Additionally, Dr. Ronald L. Rubin DMD, an Oral & Maxillofacial Surgeon and the Medifirst Medical Director, will conduct one of the studies in his Florida practice.  Dr. Rubin, a Specialist in Head and Neck Cancer, (he was granted an American Cancer Society Fellowship in Head and Neck Cancer at the Tufts-New England Medical Center in Boston) will be setting up an IRB for the treatment protocols and is the Chief Clinical Investigator that will guide the Universities with the treatment protocols and over-seeing the clinical review. It must be noted that the Company cannot guarantee the participation of the Universities until all the details and procedures have been formulated and all terms agreed to.

 

CPT Code

It is the opinion of the Company that Photobiomodulation is becoming a mainstream treatment modality in the medical community and the FDA 510(k) cleared TTML-810/2000 Infrared laser has shown that its safety and efficiency to meet the proper guideline for a CPT approval process. Although we cannot guarantee a new code will be approved, we believe that the Time Machine TTML-810/2000 Infrared Laser, in the coming months, may receive a CPT code for specific pain treatments. CPT codes are the billing codes used for reimbursement for services and treatments by the healthcare providers.   

 

Home Study

A Medifirst affiliate partner has previously filed for a $3,000,000 grant to perform a study for home usage (OTC) for the Time Machine TTML-810/2000 Infrared Laser.  The company received the first round of comments back from the NIH grant oversite committee and will be submitting its answers back for an October review meeting date. With millions of people suffering from everyday pain, Medifirst considers “home use” a major priority if the laser can be proven safe and FDA cleared for home use. Commented CEO Bruce J. Schoengood, “FDA clearance for “home use” would potentially be one of the biggest markets we can target for our Infrared Laser.  The home treatment, as well as in Nursing Homes and Assisting Living facilities, could help people suffering from pain and provide a treatment option in the convenience of their home. Many people are not physically able to travel several times a week to a doctor’s office and it can be a financial burden as well.”  Once approved, the patient would receive a prescription and pick up the laser at their doctor’s office or medical supply store. Since the process is ongoing, Medifirst cannot, at this time,  guarantee the grant will be approved.

 

 

Medifirst anticipates further updates and details regarding these developments in the upcoming weeks and months. 

 

About Oral Mucositis

Oral Mucositis affects about 400,000 patients annually in the United States, affecting their cheeks, lips, gums, inner cavity and the tonsillar region. Treatment options today are rather limited. Patients are usually given pain medication and/or an antiseptic/anti-inflammatory mouthwash. Beyond that, there's not much doctors can do for the painful condition that, at advanced stages, can inhibit a patient's ability to eat, speak or maintain health. We believe that laser therapy can be effective in treating Oral Mucositis and the Company anticipates working with industry professionals to advance and explore using laser technology for this condition. 

 

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

 

_______________________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS PROVIDES COMPANY UPDATE FOR ITS TIME MACHINE LASER AND CBD DIVISION

 

Freehold, NJ – August 7, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Premium Hemp and CBD products is pleased to provide a company update.

Medifirst recently announced a possible new expansion and direction for its Time Machine Therapeutic Laser for the application of Photobiomodulation (PBM) to treat a side effect of cancer therapy called Oral Mucositis.  Medifirst is pleased to announce that they have engaged its FDA consulting firm to assist in preparing and submitting a pre-510(k) submission to the FDA for 510(k) indication for treating Oral Mucositis with its FDA 510(k) cleared hand-held Infrared 810nm Laser. The Company believes it is an area that presents very a promising usage for its 810nm Laser as patients often develop painful or debilitating ulcers in the soft tissues within the oral cavity.  According to industry statistics, Oral Mucositis affects about 400,000 patients annually in the United States, affecting their cheeks, lips, gums, inner cavity and tonsillary region. Treatment options today are rather limited. Patients are usually given pain medication and/or antiseptic mouthwash. Beyond that, there's not much doctors can do for the painful condition that, at advanced stages, can inhibit a patient's ability to eat and speak. We believe that laser therapy can be effective in treating Oral Mucositis and the Company anticipates working with industry professionals to advance and explore using laser technology for this condition.

Medifirst is pleased to announce that a leading healthcare and medical device industry report recently has included Medifirst Solutions in its industry analysis.  The report called “Aesthetic Laser - Medical Devices Pipeline Assessment, 2019” provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Aesthetic Laser pipeline products.   See https://www.researchandmarkets.com for more details.

Medifirst Solutions is pleased to announce that its USA CBD website is now live at www.USACBDshopper.com. The CBD and Hemp products includes a 500mg oil, 1000mg oil and a premium supreme 6000mg oil. In addition to the oils, also called tinctures, the company is selling CBD and Hemp Mints. Commented Medifirst President Bruce J. Schoengood, “We are very pleased to be offering high quality products that are backed by third party lab testing. According to media reports, there are many CBD products in the marketplace that do not have the CBD potency as claimed on their labels and people are purchasing expensive products that are, in our opinion, basically worthless. Our goal is to create a quality CBD and hemp brand that consumers can trust and that will be beneficial to their lives and well-being.” The company plans to launch several additional websites to support is lineup that will include several new CBD and hemp based products in development.

Medifirst anticipates further updates and announcements in the upcoming days and weeks to the Company divisions. 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

______________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

 

 

MEDIFIRST SOLUTIONS TO PROVIDE COMPANY UPDATE

Freehold, NJ – July 17, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Premium Hemp and CBD products is pleased to provide a company update.

Medifirst Solutions previously announced that they have been approved for credit card processing for its USA PREMIUM CBD & Hemp products division. The CBD and Hemp products includes a 500mg oil, 1000mg oil and a premium 6000mg oil. In addition to the oils, also called tinctures, the company is selling CBD and Hemp Mints.

We are pleased to announce that we anticipate going live and rolling out our products within the next two weeks online at www.usapremiumcbd.com as well as several additional satellite websites to be announced. In addition, we plan to online launch sales for our Hemp products to be available on Amazon.com. Commented CEO Bruce J. Schoengood, “We are very excited to be launching our CBD line of oils and mints and we believe we have outstanding quality products all backed up by independent lab testing. In additional to our current line of oils and mints, the company plans to develop and distribute its own line of cosmetic CBD products, several new CBD liquid products and several creams and oils for pain.”

Recent industry projections forecast the CBD market to hit 16 billion dollars by 2025. Continues Schoengood, “This industry is very young and there is great interest in CBD and Hemp products.  Our mission is to develop and market high quality products that consumers can trust and all backed up by independent lab testing. “

We believe that adding high quality and some unique CBD and Hemp products to our product line is a great compliment to our therapeutic Infrared Time Machine Laser used for helping people who suffer from pain and inflammation.”

Medifirst is pleased to announce that company representatives are currently in China performing laser tests and trial treatments for a healthcare group that plans to open over 1000 pain centers across the country. In China, there is a great demand for all natural and drug-free solutions to both chronic and everyday pain and we believe our FDA cleared Time Machine 810nm Infrared laser can provide a useful and effective tool for healthcare professionals.  At this time, there is no guarantee of a final agreement and we will announce further updates as we progress.

Medifirst is also pleased to announce a possible new expansion and direction for our Therapeutic Laser. Although there are many applications and protocols for laser as related to pain and inflammation, we were most excited by the recent application of Photobiomodulation  (PBM) to treat a side effect of cancer therapy called Oral Mucositis.  This is an area that presents very a promising usage of our 810nm Laser as patients often develop painful or debilitating ulcers in the soft tissues within the oral cavity.  According to industry statistics, Oral Mucositis affects roughly 400,000 patients annually in the United States, affecting their cheeks, lips, gums, inner cavity and tonsilary region which includes all of the soft tissues. Treatment options today are rather limited. Patients are usually given pain medication and/or antiseptic mouthwash. Beyond that, there's not much doctors can do for the painful condition that, at advanced stages, can inhibit a patient's ability to eat and speak. We believe that laser therapy can be effective in treating Oral Mucositis and the Company is working with industry professionals to advance and explore using laser technology for this condition. Medifirst anticipates further updates and announcements in the upcoming days and weeks to the above mentions updates as well to our Specialty Pharma Consulting division. 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

___________________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS GETS APPROVAL FOR MERCHANT ACCOUNT FOR HEMP AND CBD PRODUCTS  

Freehold, NJ – June 6, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Premium Hemp and CBD products is pleased to provide an update.

Medifirst Solutions is pleased to announce that they have been approved for credit card processing for its USA CBD & Hemp products division. The CBD and Hemp products includes a 500mg oil, 1000mg oil and a premium 6000mg oil. In addition to the oils, also called tinctures, the company is selling CBD and Hemp Mints. Commented Medifirst President Bruce J. Schoengood, “We are very pleased with our initial development of CBD and Hemp products. The products under our USA line are of top premium quality and we believe, our 6000mg oil presents a unique and potent product for consumers, especially those who suffer from more severe conditions. Our Premium Mints include twenty five 10mg mints in a sturdy tin. The Mints provide a great alternative to Hemp and CBD gummies which is a very popular consumer product. We believe that our Mints are better tasting and more potent than most gummy products on the market.  Our goal is to have what we consider, the Gold Standard of CBD and Hemp products. “Products consumers you can trust” is our company mission.”

Recent industry projections forecast the CBD market to hit 16 billion dollars by 2025. Continues Schoengood, “Although there appears to be many CBD product on the market, the industry is still in its infancy. We believe that adding high quality and some unique CBD and Hemp products to our product line is a great compliment to our therapeutic Infrared Time Machine Laser used for helping people who suffer from pain and inflammation.” The company anticipates an announcement in the coming days to officially launch and introduce the USA CBD and Hemp website and product line.”

 

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

___________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS FINALIZES RELATIONSHIP WITH DR. GUPTA PHARMA

Freehold, NJ – November 28, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services, is pleased to introduce Dr. Sanjay Gupta, Chief Executive Officer of Dr. Gupta Pharma LLC and President of the American Pain Association, as the Company’s partner in its new Cannabidiol (“CBD”) division.

 

Medifirst recently announced that it has launched USA Pharma, Inc., its division for CBD distribution, sales and products and that it completed an agreement with Dr. Gupta Pharma LLC to distribute a line of premium CBD oils. Dr. Sanjay Gupta, not related to Dr. Gupta of CNN, is a Harvard-trained physician who specializes in the treatment of pain, has significant experience using Marijuana and CBD for treating pain. As the President of the American Pain Association, Dr. Gupta believes that CBD, used under the guidance of a physician, can play a significant role in reducing pain and helping to curb the opioid epidemic. Additionally, he believes CBD can play a major role in overall health and wellness but, he concedes, CBD remains underutilized as there is a substantial lack of education and stigma from public and healthcare providers with regards to the benefits of CBD. Unlike Marijuana, CBD does not produce a high and Dr. Gupta believes CBD is very safe to use. Dr. Gupta and the American Pain Association recently completed a 10-city tour to meet with governors and lawmakers regarding how to educate the public about benefits of CBD.  Dr. Gupta is a staunch supporter of CBD and is on the front-lines of bringing CBD to the mainstream medical community.  The American Pain Association is currently initiating several studies on CBD in conjunction with various prestigious Medical school faculties across North America. 


Based on his clinical and research work and using proprietary patented methods, Dr. Gupta has created CBD wellness products that he believes can benefit patients suffering from many different health conditions. Today, Medifirst President Bruce J. Schoengood, stated that “We are thrilled to be working with Dr. Gupta and look forward to distributing and participating in a CBD product line that, we believe, can be of great help as an all-natural product to battle pain as well as the opioid crisis. The Dr. Gupta CBD product line, we believe, will have great interest and demand by physicians and the medical community, in addition to producing unrivaled quality products for consumers.” The Company is expected to provide details about its new CBD division and the distribution agreement entered into with Dr. Gupta Pharma LLC in a Current Report on Form 8-K.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES NEW AGREEMENT FOR CBD PRODUCTS AND DISTRIBUTION

Freehold, NJ – November 21, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services is pleased to announce an update regarding its new cannabidiol (“CBD”) division.

Medifirst is pleased to announce that it has launched a majority-owned subsidiary USA Pharma, Inc., a division for its CBD distribution, sales and products. Medifirst is also pleased to announce it has completed an agreement with Dr. Gupta Pharma LLC to distribute a line of premium CBD oils. Dr. Sanjay Gupta, its Chief Executive Officer, not related to Dr. Gupta of CNN, is a physician who specializes in the treatment of pain, and is the President of the American Pain Association. Dr. Gupta has created his own line of CBD products that, Medifirst believes, is superior in quality and production process to any CBD product in the industry. Today, Medifirst President Bruce J. Schoengood, stated that “We believe that the CBD products in Dr. Gupta’s product line will have great interest and demand by physicians and the medical community, in addition to producing unrivaled quality products for consumers.” The company plans to release further detail regarding this agreement within days of this announcement.

There is already a great demand for all natural and drug free products for relieving pain, anxiety, stress and many other ailments and conditions. CBD is widely believed to have great medicinal value and potential. 

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

________________________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES NEW DIVISION FOR CBD PRODUCTS

Freehold, NJ – October 29, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and Specialty Pharmacy Drug Consulting Services is pleased to announce a company update.

Medifirst is pleased to announce that it is launching a division for CBD sales and products. There is already an explosive demand for CBD products, including healthcare and medical products, beverages and edibles, and pet products. CBD usage is surging in the United States as awareness and access to CBD products rapidly expands. CBD oil is gaining momentum with studies confirming that it may help treat a variety of ailments and conditions, such as pain, anxiety, stress, depression, cancer related symptoms, and weight loss.

The Brightfield Group recently announced projections for the hemp CBD industry to become a $5.7 billion market by next year, with a projection of nearly 400% growth to $22 billion by 2022. Hemp is variety of the cannabis plants. It does not contain any legally significant quantities of tetrahydrocannabinol (THC), the chemical that produces a high in marijuana. It does contain the active ingredient cannabidiol (CBD), which has been widely reported and shown to have great medicinal value - reports that now have been substantiated by the U.S. Food and Drug Administration. There has been a strong movement to make CBD products legal in all 50 states.

 

Today, Medifirst President Bruce J. Schoengood, stated that “CDB products are a great complement to our FDA cleared Time Machine Therapeutic Laser for all natural pain relief, and there is a tremendous demand for CBD products. Through our existing healthcare relationships, we have strong interest from oversea markets for China, Japan, and the Asia-Pacific region as well as in the U. S. market. Medifirst is working on completing related contracts and agreements and anticipates a formal announcement in the upcoming days and weeks.”

 

Medifirst recently announced it was presenting the Time Machine Laser to the Antah HealthCare Group, one of the largest medical device distributors in Malaysia. Medifirst President, Bruce J. Schoengood, stated that, “We are very pleased to report that initial testing results are positive and Medifirst representatives are meeting with Antah representatives in Hong Kong to discuss possible distribution structures and various possible business models with regards to working with Antah Healthcare. While we can make no assurances of a final agreement, we are optimistic since they are satisfied with the results. We anticipate further updates in the upcoming days and weeks.”

About CCRx

CCRx services of specialty drug pharmacy consulting and revenue stream management utilizes over 60 years of combined specialty pharmacy and infusion therapy experience. The services are designed to increase profits for pharmacies.  Services include: clinical review, expedited medical insurance verification, training for drug dispensing, insurance billing, collections, and reconciliation. The billing services will address any denials and include appeals and resubmissions. The division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding
market of the specialty pharmacy market in today's healthcare system.

 

Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, are costly, and require ongoing clinical support, we believe, will drive nearly all the pharmaceutical industry’s market growth from 2015–2020.

 

 Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue. If these projections hold true, specialty drugs will have increased their revenues by over 5X from 2010–2020, growing from just 15% of the market to nearly half in that decade.

 

About The Time Machine Laser

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES UPDATE FOR ITS TIME MACHINE LASER DIVISION

 

Freehold, NJ – August 23, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and Specialty Pharmacy Drug Consulting Services is pleased to announce an update for its laser division.

 

Medifirst is pleased to announce that they have been working with the Antah HealthCare Group and Fullerton Health to introduce the Time Machine Laser as a drug-free and natural treatment for pain and inflammation. Antah HealthCare Group is one of the largest Malaysian owned healthcare marketing and distribution companies in Malaysia. They have over 250 employees with branch offices located at major cities nationwide. The group has over 50 years of experience in the healthcare industry. Additionally, Fullerton Health is in the process of testing the Time Machine Laser at its Singapore facilities.  Fullerton Health is a leading vertically integrated healthcare platform in the Asia Pacific region. Founded in Singapore in 2011, they own and operate an extensive network of healthcare facilities across 8 countries and partner with established and reputable healthcare providers in the region.  As a pioneer of healthcare innovation, they leverage technology to provide cost-effective management and administration of healthcare services. Commented Medifirst President, Bruce J. Schoengood, “We are very pleased and excited to be working with such established healthcare leaders and introduce our laser to the Asia Pacific market. Both companies are committed to seeking drug free and natural pain solutions that effect tens of thousands of lives. Although definitive agreements have not been finalized, we are very optimistic about our progress and the enthusiasm of these healthcare companies with regards to our laser. We anticipate further announcements in the upcoming days and weeks.”

 

NAALT 2018 CONFERENCE
North American Association for Photobiomodulation Therapy


This past week, our V.P and Medical Director, Dr. Ronald Rubin was invited and honored to speak and introduce The Time Machine Laser at this prestigious conference.  The NAALT 2018 conference focus was Photobiomodulation and Drug-Free Management of Pain with the emphasis on treatment of pain and the acceleration of tissue healing.

As been widely reported, President Trump has declared a State of Opioid Emergency. A public health emergency exists, and it is our belief, that laser technology can provide a viable pain treatment solution that is drug-free. The purpose of NAALT is to be a forum for therapeutic light therapy practitioners in North America (Mexico, USA and Canada), as well as many other countries that attended the conference. Its goal is to promote phototherapy as a valid treatment, and to improve understanding of photobiological mechanisms, basic therapeutic light physics, safety, treatment parameters, techniques, regulatory issues and reimbursement. Panels of researchers and clinicians from around the world gathered together to share their research and clinical experience in the effective drug-free management of pain.

Commented Dr. Rubin, “This was an amazing opportunity to introduce our Time Machine Laser device to such leading and esteemed experts including Dr. Michael Hamblin, of the Wellman Center for Photomedicine, a teaching Affiliate of the Harvard Medical School. Dr. Hamblin is widely recognized as the leading expert in low light laser therapy and photobiomodulation.  I was delighted to meet colleagues from around the world and I am confident that this conference will lead to many new opportunities for Medifirst and the Time Machine Laser.”

About CCRx

CCRx services of specialty drug pharmacy consulting and revenue stream management utilizes over 60 years of combined specialty pharmacy and infusion therapy experience. The services are designed to increase profits for pharmacies.  Services include: clinical review, expedited medical insurance verification, training for drug dispensing, insurance billing, collections, and reconciliation. The billing services will address any denials and include appeals and resubmissions. The division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding
market of the specialty pharmacy market in today's healthcare system.

 

Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, are costly, and require ongoing clinical support, we believe, will drive nearly all the pharmaceutical industry’s market growth from 2015–2020.

 

 Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue. If these projections hold true, specialty drugs will have increased their revenues by over 5X from 2010–2020, growing from just 15% of the market to nearly half in that decade.

 

About The Time Machine Laser

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

________________________________________

 

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES NEW CONSULTING AGREEMENT FOR ITS SPECIALTY DRUG DIVISION

 

 

Freehold, NJ – August 2, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology and specialty pharmacy drug and consulting services is pleased to announce that Concierge Concepts Rx (CCRx), a division of Medifirst Solutions, has signed an exclusive three-year Specialty Pharmacy Consulting Agreement with QuickChek, a New Jersey based company that owns 153 convenience stores including pharmacy services. They have 4000 employees in New Jersey and New York locations.

 

As part of the agreement, CCRx will provide consulting services to QuickChek pharmacies so they can enter and participate in the ever-expanding market of specialty drugs.  CCRx will provide services that include: clinical review, expedited medical insurance verification, training for drug dispensing, insurance billing, collections, and reconciliation. The billing services will address any denials and include appeals and re-submissions.

 

Commented CCRx President Walter Molokie, “We plan to bring in new business and revenue streams to the QuickChek line of pharmacies and develop as well as implement a new sales strategy to generate sales for specialty drugs. We are excited and very pleased to be working with QuickChek, a company of great quality and outstanding service to the community. Additionally, we are very confident that our strategy to expand their pharmacy services will result in increased revenues. Commented Medifirst President Bruce J. Schoengood, “We believe CCRx, with its focus on specialty drugs, can provide great growth for Medifirst as well as open up many doors for new related opportunities. Many companies have been contacting CCRx to inquire about its services and expertise and we anticipate additional announcements and further updates on QuickChek in the upcoming days and weeks.”

 

About CCRx

CCRx services of specialty drug pharmacy consulting and revenue stream management utilizes over 60 years of combined specialty pharmacy and infusion therapy experience. The services are designed to increase profits for pharmacies.  Services include: clinical review, expedited medical insurance verification, training for drug dispensing, insurance billing, collections, and reconciliation. The billing services will address any denials and include appeals and resubmissions. The division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding
market of the specialty pharmacy market in today's healthcare system.

 

Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, are costly, and require ongoing clinical support, we believe, will drive nearly all the pharmaceutical industry’s market growth from 2015–2020.

Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue. If these projections hold true, specialty drugs will have increased their revenues by over 5X from 2010–2020, growing from just 15% of the market to nearly half in that decade.

 

About The Time Machine Laser

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

_______________________________________

_________________________________________________________

Home         Infrared Laser         Meet The Team         Our Mission        Investor Relations       Breaking News       Contact Us

Copyright Medifirst Solutions, Inc  2017